Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results

Core Insights - Silence Therapeutics plc reported financial results for Q4 and the full year ended December 31, 2025, highlighting a focus on clinical execution and progress in their pipeline [1] Financial Performance - The company provided an update on its financial results, indicating a strong emphasis on clinical trials and operational advancements [1] Clinical Development - The Phase 2 SANRECO trial of divesiran in PV is progressing well, with expedited enrollment and expected topline results in the third quarter [1]